The Role of Dynorphin / Kappa-Opioid Systems in Alcohol Dependence
强啡肽/κ-阿片类药物系统在酒精依赖中的作用
基本信息
- 批准号:8240413
- 负责人:
- 金额:$ 33.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdultAffectAffectiveAffective SymptomsAlcohol consumptionAlcohol dependenceAlcohol withdrawal syndromeAlcoholismAlcoholsAmygdaloid structureAnimal ModelAnimalsAnxietyAnxiety DisordersAttenuatedBehaviorCell NucleusCharacteristicsChronicComorbidityDataDependenceDevelopmentDiagnosisDiseaseDynorphinsEmotionalExcisionGoalsHeavy DrinkingIndividualInfusion proceduresInvestigationKnowledgeLigandsMeasuresMental DepressionMoodsNeurotransmittersOpioidOpioid ReceptorOutcomePathogenesisPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhenotypePrincipal InvestigatorProcessPsychological reinforcementPublic HealthRattusRecoveryRelapseRoleSelf AdministrationSelf MedicationSiteSwimmingSystemTestingWithdrawalWorkalcohol effectalcohol exposurealcohol reinforcementalcohol relapsealcohol use disorderalcoholism therapybasecompliance behaviorcostdepressive symptomsdesignkappa opioid receptorsmedication complianceneuroadaptationneurotransmissionpublic health relevanceresearch studyresponsesuccesstherapy developmenttreatment adherencetreatment strategyvapor
项目摘要
DESCRIPTION (provided by applicant): A fundamental characteristic of excessive alcohol use is the comorbidity of alcohol dependence and disorders of affect. Self-medication of these negative affective states likely contributes to excessive alcohol use and relapse. Negative affective states produced by chronic alcohol exposure result from neuroadaptations in motivational and affective neurocircuitry that are not yet understood. The principal investigator's long-term goal is to identify effective pharmacotherapeutic targets for the treatment of alcoholism. The objective of this application, which is the next step in pursuit of that goal, is to understand the neuroadaptations in dynorphin / kappa-opioid systems that occur in response to chronic alcohol exposure and contribute to attenuated motivational and affective states. The central hypothesis is that compensatory neuroadaptations in dynorphin / kappa-opioid systems oppose the acute effects of alcohol, and promote excessive alcohol intake by altering negative affective behaviors. The rationale for the proposed studies is that identification of dynorphin targets will enable the development of pharmacotherapies designed to alleviate motivational and affective symptoms produced by alcohol dependence. The hypothesis will be tested by pursuing the following specific aims: Aim #1 will evaluate kappa opioid receptor antagonism within specific sites of the extended amygdala during acute withdrawal. Aim #2 will site-specifically evaluate the role of extended amygdala dynorphin systems in depressive- and anxiety-like behavior. Specific Aim #3 will maximize dependence-induced alterations in negative affective behaviors during acute and protracted withdrawal. All three aims will utilize animal models of ethanol reinforcement and affective behavior to allow for the systematic investigation of neurotransmitter systems and neurocircuitry that contribute to altered motivational and affective states produced by chronic ethanol exposure. These three specific aims will collectively help to identify important neuroadaptations that result from chronic alcohol exposure and provide much needed information regarding the neurocircuitry involved in altered motivational and affective systems. Such a contribution is significant because it will help to develop pharmacotherapeutic targets for the treatment of alcoholism that focus on the removal of attenuated motivational and negative affective states; a strategy that should greatly increase medication compliance and decrease rates of relapse.
PUBLIC HEALTH RELEVANCE: This proposal is relevant to public health and will have an important positive impact because there are currently no pharmacotherapies designed to alleviate the negative affective and attenuated motivational aspects of alcohol withdrawal and dependence. In addition to the site-specific investigation of dynorphin / kappa-opioid systems in reinforcement paradigms, the benefits of this proposal are the assessment of dynorphin / kappa-opioid systems in depressive- and anxiety-like behaviors associated with alcohol dependence. The proposed experiments will assist with the development of pharmacological targets for alcoholism based on the alleviation of negative affect and result in increased compliance and treatment success for the individual and less alcoholism-associated societal costs.
描述(由申请人提供):过度饮酒的一个基本特征是酒精依赖和情感障碍的共病。这些消极情感状态的自我药物治疗可能会导致过度饮酒和复发。慢性酒精暴露产生的消极情感状态是由动机和情感神经回路中的神经适应引起的,目前尚不清楚。主要研究者的长期目标是确定治疗酒精中毒的有效药物治疗靶点。这个应用程序的目标是,这是追求这一目标的下一步,是了解在长期酒精暴露反应中发生的dynorphin / kappa-opioid系统的神经适应,并有助于减弱动机和情感状态。核心假设是,dynorphin / kappa-opioid系统中的代偿性神经适应对抗酒精的急性效应,并通过改变负面情感行为来促进过量饮酒。所提议的研究的基本原理是,确定动力啡的靶点将有助于开发旨在减轻酒精依赖产生的动机性和情感性症状的药物疗法。该假设将通过追求以下具体目标来验证:目的1将评估急性戒断期间扩展杏仁核特定部位的kappa阿片受体拮抗作用。目标2将具体地评估扩展杏仁核运动啡系统在抑郁和焦虑样行为中的作用。具体目标#3将最大限度地提高急性和长期戒断期间负面情感行为的依赖诱导改变。这三个目标都将利用乙醇强化和情感行为的动物模型,对慢性乙醇暴露导致动机和情感状态改变的神经递质系统和神经回路进行系统研究。这三个具体目标将共同帮助确定慢性酒精暴露导致的重要神经适应,并提供有关改变动机和情感系统的神经回路的急需信息。这样的贡献是重要的,因为它将有助于开发药物治疗目标,以治疗酒精中毒,重点是消除减弱的动机和消极的情感状态;这一策略将大大提高药物依从性并降低复发率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brendan M Walker其他文献
Brendan M Walker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brendan M Walker', 18)}}的其他基金
Oprk1-regulated neurocircuitry and phenotypes of alcohol use disorder
Oprk1 调节的神经回路和酒精使用障碍的表型
- 批准号:
10753867 - 财政年份:2023
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Kappa-Opioid Receptors in Alcohol Use Disorders
Kappa-阿片受体在酒精使用障碍中的作用
- 批准号:
9986995 - 财政年份:2019
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Kappa-Opioid Receptors in Alcohol Use Disorders
Kappa-阿片受体在酒精使用障碍中的作用
- 批准号:
10473825 - 财政年份:2019
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Kappa-Opioid Receptors in Alcohol Use Disorders
Kappa-阿片受体在酒精使用障碍中的作用
- 批准号:
10241455 - 财政年份:2019
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Dynorphin / Kappa-Opioid Systems in Alcohol Dependence
强啡肽/κ-阿片类药物系统在酒精依赖中的作用
- 批准号:
8442394 - 财政年份:2011
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Dynorphin / Kappa-Opioid Systems in Alcohol Dependence
强啡肽/κ-阿片类药物系统在酒精依赖中的作用
- 批准号:
8085608 - 财政年份:2011
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Dynorphin / Kappa-Opioid Systems in Alcohol Dependence
强啡肽/κ-阿片类药物系统在酒精依赖中的作用
- 批准号:
8828026 - 财政年份:2011
- 资助金额:
$ 33.15万 - 项目类别:
The Role of Dynorphin / Kappa-Opioid Systems in Alcohol Dependence
强啡肽/κ-阿片类药物系统在酒精依赖中的作用
- 批准号:
9243184 - 财政年份:2011
- 资助金额:
$ 33.15万 - 项目类别:
Chronic Ethanol Consumption, Opioids and Dopamine
慢性乙醇消耗、阿片类药物和多巴胺
- 批准号:
7168858 - 财政年份:2004
- 资助金额:
$ 33.15万 - 项目类别:
Chronic Ethanol Consumption, Opioids and Dopamine
慢性乙醇消耗、阿片类药物和多巴胺
- 批准号:
6738605 - 财政年份:2004
- 资助金额:
$ 33.15万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 33.15万 - 项目类别:
Research Grant